• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Preliminary population pharmacokinetic (popPK) co-variates and exposure response (ER) assessment of QT for RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Lee, E
    Yap, T
    Fontana, E.
    Rosen, E
    Spigel, D
    Lheureux, S
    Mettu, N
    Carter, Louise
    Plummer, R
    Patel, S
    McDougall, R
    Papp, R
    May, S
    Nejad, P
    Ulanet, D
    Wainszelbaum, M
    Manley, P
    Koehler, M
    Fretland, A
    Hojgaard, M
    Show allShow less
    Affiliation
    Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    "Background: RP-3500 is an oral inhibitor of ATR (ATRi) in development for the treatment of patients (pts) with advanced solid tumors carrying alterations in ATRi sensitizing genes. We report popPK co-variates and effect on QT prolongation in 120 pts treated with RP-3500 in the phase 1 TRESR study (NCT04497116). Methods: PK samples were collected from 120 pts on multiple days across doses and schedules during the dose-finding portion of the study. Pt demographics and baseline characteristics were collected at study enrollment. Triplicate electrocardiograms (ECGs) were collected prior to any drug administration and in conjunction with PK sampling at time points up to 4 hr post-RP-3500 dose. A popPK model was developed using Phoenix WinNonLin. PK co-variates were analyzed to assess the effect of age sex, body weight (BW), body surface area (BSA), and renal/hepatic function on RP-3500 PK. Changes in ECG parameters were evaluated in an ER assessment. Results: Plasma PK samples (N¼2627) from 120 pts were analyzed; 85 pts were sampled on at least 3 different days. The PK data set encompassed an RP-3500 dose range of 5e200 mg QD and BID across 2 different weekly regimens: 5 days on/2 days off, 3 days on/4 days off. RP-3500 PK was well described using a 2-compartment model with a lag-time incorporated to accurately describe drug absorption. Pre liminary co-variate analysis suggested some variation in RP-3500 PK according to BW and BSA. There was no significant impact on PK values in patients with mild renal or hepatic impairment. Among patients with moderate renal impairment, a small reduction in clearance was observed with limited impact on other compartmental PK values. Results of the initial ER assessment showed no RP-3500-related changes in QT intervals. Conclusions: These popPK results from TRESR confirm a predictable RP-3500 PK profile with low variability. Importantly, the data indicate that RP-3500-induced changes in QT are unlikely, and strongly support further clinical development of RP-3500 with limited ECG evaluation. Further investigation into the potential need for moderate renal impairment-, BW- or BSA-adjusted RP-3500 dosing is ongoing."
    Citation
    Lee, E, Yap, T. A, Fontana, E, Rosen, E, Spigel, D, Lheureux, S, Mettu, N B, Carter, Louise, Plummer, R Patel, S, McDougall, R, Papp, R, May, SPreliminary population pharmacokinetic (popPK) co-variates and exposure response (ER) assessment of QT for RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase. Annals of Oncology. 2022 , Nejad, P, Ulanet, D, Wainszelbaum, M, Manley, P., Koehler, M, Fretland, A J, Hojgaard, M.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/625196
    DOI
    10.1016/j.annonc.2022.01.072
    Additional Links
    https://dx.doi.org/10.1016/j.annonc.2022.01.072
    Type
    Meetings and Proceedings
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.annonc.2022.01.072
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.